Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K, Eknert J, Öfverholm E, Papantoniou D, Jawdat F, Verbiéné I, Laurell A, Jänes E, Sandzén J, Wojtyna-Dziedzic E, Lagstam I, Söderkvist K, Costa Svedman F, Liedberg F, Bruzelius M, Fransson AS, Kjellström S, Omland LH, Pappot H, Ullén A. Holmsten K, et al. Among authors: laurell a. Clin Genitourin Cancer. 2023 Dec;21(6):e438-e448. doi: 10.1016/j.clgc.2023.05.008. Epub 2023 May 17. Clin Genitourin Cancer. 2023. PMID: 37308329 Free article.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Lindberg Å, Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbaek K, Geisler CH, Jerkeman M. Lindberg Å, et al. Among authors: laurell a. Hematol Oncol. 2022 Feb;40(1):22-30. doi: 10.1002/hon.2940. Epub 2021 Nov 10. Hematol Oncol. 2022. PMID: 34713465 Clinical Trial.
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group. Kolstad A, et al. Among authors: laurell a. Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27. Biol Blood Marrow Transplant. 2017. PMID: 28039078 Free article. Clinical Trial.
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A. Jerkeman M, et al. Among authors: laurell a. Lancet Haematol. 2018 Mar;5(3):e109-e116. doi: 10.1016/S2352-3026(18)30018-8. Epub 2018 Jan 29. Lancet Haematol. 2018. PMID: 29396091 Clinical Trial.
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A. Laurell A, et al. J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017. J Immunother Cancer. 2017. PMID: 28642820 Free PMC article. Clinical Trial.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M. Albertsson-Lindblad A, et al. Among authors: laurell a. Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27. Blood. 2016. PMID: 27354719 Free article. Clinical Trial.
The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia.
Skogsberg S, Tobin G, Kröber A, Kienle D, Thunberg U, Aleskog A, Karlsson K, Laurell A, Merup M, Vilpo J, Sundström C, Roos G, Jernberg-Wiklund H, Döhner H, Nilsson K, Stilgenbauer S, Rosenquist R. Skogsberg S, et al. Among authors: laurell a. Leukemia. 2006 Jan;20(1):77-81. doi: 10.1038/sj.leu.2404030. Leukemia. 2006. PMID: 16307023
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.
Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; SWENOTECA. Tandstad T, et al. Among authors: laurell a. Ann Oncol. 2014 Nov;25(11):2167-2172. doi: 10.1093/annonc/mdu375. Epub 2014 Aug 11. Ann Oncol. 2014. PMID: 25114021 Free article.
179 results